Overview

CCI-779 in Treating Patients With Prostate Cancer

Status:
Completed

Trial end date:
2004-03-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to determine the effectiveness of CCI-779 in treating patients who have progressive prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Sirolimus